ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,668.75
1.24%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. KalVista Pharmaceuticals Inc (KALV)

  7. KalVista Pharmaceuticals Inc (KALV) Noticias

KALV KalVista Pharmaceuticals Inc

12.13
-0.04 (-0.33%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
KalVista Pharmaceuticals Inc KALV NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.04 -0.33% 12.13 15:35:11
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
12.24 11.955 12.48 12.13 12.17
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
02/5/202405:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..
01/5/202405:30BWKalVista Pharmaceuticals Highlights Strategic Plans for..
22/4/202405:30BWKalVista Pharmaceuticals Appoints William C. Fairey to Board..
03/4/202405:30BWKalVista Pharmaceuticals to Present at 23rd Annual Needham..
02/4/202405:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..
18/3/202405:30BWKalVista Pharmaceuticals Presents Real-World Data on Burden..
12/3/202405:30BWKalVista Pharmaceuticals Awarded UK Promising Innovative..
11/3/202415:37EDGAR2Form 8-K - Current report
11/3/202415:26EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/3/202405:30BWKalVista Pharmaceuticals Reports Third Fiscal Quarter..
08/3/202415:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202405:30BWKalVista Pharmaceuticals to Present HAE Attack Journey Data..
07/3/202405:38EDGAR2Form 8-K - Current report
07/3/202405:30BWKalVista Pharmaceuticals Announces Appointment of Benjamin..
06/3/202405:30BWKalVista Pharmaceuticals to Participate in the Leerink..
04/3/202405:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..
27/2/202405:30BWKalVista Pharmaceuticals Presents Data on Unmet Needs in HAE..
26/2/202405:30BWKalVista Pharmaceuticals Presents Additional Phase 3..
22/2/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202412:22EDGAR2Form SC 13D/A - General statement of acquisition of..
21/2/202420:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202420:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202420:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202420:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202420:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202415:49EDGAR2Form SC 13D/A - General statement of acquisition of..
20/2/202405:30BWKalVista Pharmaceuticals Awarded UK Innovation Passport for..
16/2/202415:32EDGAR2Form 8-K - Current report
16/2/202415:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
16/2/202415:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202415:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202415:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202415:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202405:30BWKalVista Pharmaceuticals to Present Phase 3 Sebetralstat..
15/2/202405:30BWKalVista Pharmaceuticals Announces Pricing of a $160.1..
14/2/202419:52EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202416:13EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/2/202415:18BWKalVista Pharmaceuticals Announces Proposed Public Offering..
14/2/202415:14EDGAR2Form 8-K - Current report
13/2/202408:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202405:55EDGAR2Form 8-K - Current report
13/2/202405:30BWKalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial..
12/2/202419:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/2/202419:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202416:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202405:30BWKalVista Pharmaceuticals Reports Inducement Grants Under..

Su Consulta Reciente

NASDAQ
KALV
KalVista Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados